Cargando…
Immunotherapy Associated Neurotoxicity in Pediatric Oncology
Novel immunotherapies are increasingly being employed in pediatric oncology, both in the upfront and relapsed/refractory settings. Through various mechanisms of action, engagement and activation of the immune system can cause both generalized and disease site-specific inflammation, leading to immune...
Autores principales: | Shalabi, Haneen, Nellan, Anandani, Shah, Nirali N., Gust, Juliane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899040/ https://www.ncbi.nlm.nih.gov/pubmed/35265526 http://dx.doi.org/10.3389/fonc.2022.836452 |
Ejemplares similares
-
Immunotherapy for Pediatric Leukemia
por: Shah, Nirali N., et al.
Publicado: (2013) -
ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY
por: Cole, Allison, et al.
Publicado: (2020) -
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
por: Shalabi, Haneen, et al.
Publicado: (2015) -
Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020) -
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)